|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 51/04 | |
| A61P 35/00 | |||
| A61P 39/00 | |||
| A61K 31/541 | |||
| A61K 31/4188 | |||
| A61K 31/225 |
| (11) | Number of the document | 3193914 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15840011.9 |
| Date of filing the European patent application | 2015-09-04 | |
| (97) | Date of publication of the European application | 2017-07-26 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-20 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/048651 |
| Date | 2015-09-04 |
| (87) | Number | WO 2016/040179 |
| Date | 2016-03-17 |
| (30) | Number | Date | Country code |
| 201462047546 P | 2014-09-08 | US |
| (72) |
BABICH, John W., US
HILLIER, Shawn, US
JOYAL, John, US
|
| (73) |
Molecular Insight Pharmaceuticals, Inc.,
One World Trade Center 47th Floor, Suite J, New York, New York 10007,
US
|
| (54) | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER |
| ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER |